10-K: Chemed Corporation's 10-K Filing Reveals Financial Performance and Strategic Outlook for 2024

Sentiment:

Annual Results 28 February 2025 9:01 AM

Chemed Corporation's 2024 10-K filing highlights the company's financial performance, business segments, risk factors, and future outlook, with a focus on its VITAS and Roto-Rooter operations.

Summary

Chemed Corporation's 10-K filing for the fiscal year ended December 31, 2024, provides a comprehensive overview of the company's business, financial performance, and risk factors.
The company operates through two main segments: VITAS, which provides hospice and palliative care, and Roto-Rooter, which offers plumbing and drain cleaning services.
In 2024, Chemed reported service revenues and sales of $2,431.3 million and net income of $302.0 million, or $20.10 per share.
The VITAS segment saw a 16.4% increase in revenue, driven by a 14.1% increase in days-of-care and a 2.8% increase in Medicare reimbursement rates.
Roto-Rooter experienced a 5.2% decrease in revenue, attributed to declines in various service lines.
The company completed several acquisitions in 2024, including hospice operations from Covenant Care for $85.0 million and multiple Roto-Rooter franchises.
Chemed's future outlook includes projected revenue growth for both VITAS and Roto-Rooter in 2025, with an estimated earnings per diluted share range of $24.94 to $25.45.
The filing also details various risk factors, including competition, government regulations, cybersecurity threats, and potential liability claims.

Sentiment

Score: 7

Explanation: The document presents a balanced view of Chemed's performance, highlighting both positive growth and potential risks. The future outlook is cautiously optimistic, contributing to a moderately positive sentiment.

Positives

VITAS experienced significant revenue growth, driven by increased days-of-care and Medicare reimbursement rates.
The acquisition of Covenant Care is expected to contribute to future revenue and earnings.
Chemed maintains a strong financial position with sufficient cash flow and available credit to fund operations and strategic initiatives.
The company has a history of returning value to shareholders through stock repurchases and dividends.
Chemed is actively working to improve cybersecurity measures and mitigate potential risks.

Negatives

Roto-Rooter experienced a decrease in revenue due to declines in service lines.
The company faces intense competition in both the hospice and plumbing industries.
Chemed is subject to extensive government regulations, which could impact its operations and profitability.
The company is exposed to potential liability claims and litigation, which could have a material adverse effect on its financial condition.
VITAS is highly dependent on payments from Medicare and Medicaid, which are subject to change and potential reductions.

Risks

Intense competition in the sewer, drain, pipe cleaning, plumbing repair, excavation and water restoration businesses.
Changes in Medicare and Medicaid payment rates or methods could materially affect VITAS's net patient service revenue and profits.
Inability to maintain relationships with existing patient referral sources or establish new referral sources could adversely affect VITAS's growth and profitability.
Extensive government regulation and claims reviews in the healthcare industry could reduce VITAS's net patient service revenue and profitability.
Cybersecurity attacks could compromise sensitive patient information and disrupt business operations.
Loss of key management personnel or inability to hire and retain skilled employees could adversely affect both Roto-Rooter and VITAS.
Environmental and safety compliance costs and liabilities could increase expenses and adversely affect financial condition.
Anti-takeover statutes might make it more difficult to effect a change in control of the Company.
Adverse rulings in certain litigation could have an adverse effect on financial condition and results of operations.
Issues associated with the actual or perceived effects of another epidemic, pandemic, or similar widespread public health concern, could adversely affect our businesses.

Future Outlook

Chemed projects revenue growth for both VITAS and Roto-Rooter in 2025, with an estimated earnings per diluted share range of $24.94 to $25.45.

Industry Context

The hospice care industry is highly competitive and subject to extensive government regulation. The plumbing and drain cleaning industry is fragmented with local and regional firms providing the primary competition. Private equity businesses have recently made significant investments in home service companies, including plumbing.

Comparison to Industry Standards

The document does not provide enough information to make a detailed comparison to industry standards.
However, it notes that VITAS competes with a large number of organizations, including national and regional hospice providers, hospitals, nursing homes, and home health agencies.
Roto-Rooter competes with local and regional firms, and private equity businesses have recently made significant investments in home service companies, including plumbing.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Financial Officer	David P. Williams	Michael D. Witzeman	January 2024	David P. Williams transitioned to an employee advisor role.

Legal Proceedings

VITAS is one of a group of hospice providers selected by the Office of the Inspector Generals (OIG) Office of Audit Services (OAS) for inclusion in an audit of the provision of elevated level-of-care hospice services.
On July 14, 2022, VITAS received the final audit report from OAS.
On August 29, 2022, VITAS received a demand letter from its Medicare Administrative Contractor (MAC) seeking repayment of $50.3 million.
On February 3, 2025, an Administrative Law Judge ruled that VITAS care met Medicares hospice standards for the applicable higher level of care as originally billed for all but one of the claims appealed.

Stakeholder Impact

Shareholders: The company's financial performance and capital allocation decisions directly impact shareholder value.
Employees: The company's hiring, retention, and compensation policies affect its workforce.
Customers/Patients: The quality of services provided by VITAS and Roto-Rooter impacts patients and customers.
Suppliers: The company's relationships with vendors and suppliers are important for its operations.
Creditors: The company's debt levels and compliance with debt covenants affect its creditworthiness.

Next Steps

Chemed will continue to focus on growing its VITAS and Roto-Rooter segments.
The company will actively manage its capital allocation, considering share repurchases, debt repayment, acquisitions, and dividends.
Chemed will continue to monitor and address cybersecurity risks.
The company will work to comply with all applicable government regulations and legal requirements.

Key Dates

Date	Description
1970	Chemed Corporation was incorporated in Delaware.
April 30, 1971	Chemed succeeded to the business of W.R. Grace & Co.'s Special Products Group.
March 10, 1982	Chemed remained a subsidiary of W.R. Grace & Co. until this date.
1991	Sale of DuBois Chemicals Inc.
1995	Private Securities Litigation Reform Act of 1995.
1996	Health Insurance Portability and Accountability Act of 1996 (HIPAA).
1999	Chemed/Roto-Rooter Savings & Retirement Plan, effective January 1, 1999.
June 1, 2001	Excess Benefits Plan, as restated and amended, effective June 1, 2001.
2002	Sarbanes-Oxley Act of 2002.
April 1, 2013	The Federal government implemented a 2% reimbursement cut for all Medicare programs, including hospice.
May 2014	FASB issued Accounting Standards Update ASU No. 2014-09 Revenue from Contracts with Customers.
February 2016	The FASB issued Accounting Standards Update ASU No. 2016-02 Leases.
June 2016	The FASB issued Accounting Standards Update ASU No. 2016-13, Financial Instruments, Credit Losses.
October 30, 2017	Settlement agreement to resolve civil litigation under the False Claims Act.
August 6, 2019	The Centers for Medicare and Medicaid Services released the fiscal year 2020 hospice wage index and payment rate update (FY 2020 update).
May 1, 2020	2% reimbursement cut was suspended or reduced to 1% through a series of legislative measures for the period May 1, 2020 through June 30, 2022.
June 28, 2022	Fifth Amended and Restated Credit Agreement by and among Chemed Corporation, JP Morgan Chase Bank NA, and other lenders.
July 1, 2022	VITAS adopted the Difference Maker Program in July 2022 which provided stay-bonuses, for eligible existing employees and new employees who were hired during the application of the program.
August 29, 2022	VITAS received a demand letter from its Medicare Administrative Contractor (MAC) seeking repayment of $50.3 million.
June 22, 2023	The OIG confirmed that VITAS satisfied its obligation under the CIA and that the CIA was concluded.
September 30, 2024	Medicare payments to a hospice are also subject to a separate cap based on overall average payments per admission. This cap was set at $33,494.01 per admission for the twelve month period ended on September 30, 2024.
September 11, 2024	The Centers for Medicare and Medicaid Services released the 2025 inflationary increase effective October 1, 2024, which was 2.9%.
October 1, 2024	The date of our annual goodwill and indefinite-lived intangible asset impairment analysis.
November 2024	Our Board of Directors authorized an additional $300 million under the February 2011 Repurchase Program.
December 31, 2024	End of fiscal year 2024.
February 3, 2025	An Administrative Law Judge ruled that VITAS care met Medicares hospice standards for the applicable higher level of care as originally billed for all but one of the claims appealed.
February 14, 2025	CMS announced that it had ceased implementation of the SFP to further evaluate the program.
February 28, 2025	Date of the independent registered public accounting firm report.
May 19, 2025	Scheduled date for the next annual organizational meeting of the Board of Directors of the Company.
September 30, 2025	Medicare payments to a hospice are also subject to a separate cap based on overall average payments per admission. This cap was set at $34,465.34 for the twelve month period ending on September 30, 2025.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.